Search details
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Article
in English
| MEDLINE | ID: mdl-37256976
2.
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.
Cell
; 140(4): 477-90, 2010 Feb 19.
Article
in English
| MEDLINE | ID: mdl-20178741
3.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35671774
4.
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
Br J Clin Pharmacol
; 88(2): 858-864, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34309049
5.
Status of adjuvant endocrine therapy for breast cancer.
Breast Cancer Res
; 16(2): 206, 2014.
Article
in English
| MEDLINE | ID: mdl-25032258
6.
Evaluation of patient enrollment in oncology phase I clinical trials.
Oncologist
; 18(3): 323-9, 2013.
Article
in English
| MEDLINE | ID: mdl-23429738
7.
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors.
Mod Pathol
; 26(3): 456-63, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23174939
8.
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
Support Care Cancer
; 21(5): 1313-9, 2013 May.
Article
in English
| MEDLINE | ID: mdl-23196819
9.
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Lancet Oncol
; 13(10): 1020-4, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22995650
10.
Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer.
PLoS One
; 18(1): e0280259, 2023.
Article
in English
| MEDLINE | ID: mdl-36649275
11.
A View on Drug Development for Cancer Prevention.
Cancer Discov
; 13(5): 1058-1083, 2023 05 04.
Article
in English
| MEDLINE | ID: mdl-37067191
12.
PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
J Cell Physiol
; 227(4): 1657-62, 2012 Apr.
Article
in English
| MEDLINE | ID: mdl-21678421
13.
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
J Cell Physiol
; 227(3): 927-33, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-21503888
14.
Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.
Gastric Cancer
; 15(4): 419-26, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22237659
15.
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Mol Oncol
; 16(10): 1969-1985, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34866317
16.
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.
J Cell Physiol
; 226(3): 780-4, 2011 Mar.
Article
in English
| MEDLINE | ID: mdl-20857484
17.
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
JCO Precis Oncol
; 52021.
Article
in English
| MEDLINE | ID: mdl-34250397
18.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
; 7(1): 44, 2021 Apr 16.
Article
in English
| MEDLINE | ID: mdl-33863913
19.
Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.
Nat Commun
; 11(1): 1446, 2020 03 27.
Article
in English
| MEDLINE | ID: mdl-32221288
20.
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.
Clin Cancer Res
; 26(19): 5172-5177, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-32546646